- Home
- CRDF vs XGN Comparison
CRDF vs XGN Comparison
Compare CRDF & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- XGN
- Stock Information
- Founded
- CRDF 1999
- XGN 2002
- Country
- CRDF United States
- XGN United States
- Employees
- CRDF N/A
- XGN N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- XGN Medical Specialities
- Sector
- CRDF Health Care
- XGN Health Care
- Exchange
- CRDF Nasdaq
- XGN Nasdaq
- Market Cap
- CRDF 169.6M
- XGN 138.3M
- IPO Year
- CRDF N/A
- XGN 2019
- Fundamental
- Price
- CRDF $3.21
- XGN $6.84
- Analyst Decision
- CRDF Strong Buy
- XGN Strong Buy
- Analyst Count
- CRDF 5
- XGN 2
- Target Price
- CRDF $10.50
- XGN $7.50
- AVG Volume (30 Days)
- CRDF 1.2M
- XGN 227.8K
- Earning Date
- CRDF 08-07-2025
- XGN 08-04-2025
- Dividend Yield
- CRDF N/A
- XGN N/A
- EPS Growth
- CRDF N/A
- XGN N/A
- EPS
- CRDF N/A
- XGN N/A
- Revenue
- CRDF $587,000.00
- XGN $56,724,000.00
- Revenue This Year
- CRDF N/A
- XGN $19.39
- Revenue Next Year
- CRDF N/A
- XGN $13.27
- P/E Ratio
- CRDF N/A
- XGN N/A
- Revenue Growth
- CRDF N/A
- XGN 1.78
- 52 Week Low
- CRDF $2.01
- XGN $1.71
- 52 Week High
- CRDF $5.64
- XGN $7.95
- Technical
- Relative Strength Index (RSI)
- CRDF 44.28
- XGN 52.84
- Support Level
- CRDF $2.96
- XGN $6.73
- Resistance Level
- CRDF $3.24
- XGN $7.35
- Average True Range (ATR)
- CRDF 0.28
- XGN 0.47
- MACD
- CRDF -0.10
- XGN -0.09
- Stochastic Oscillator
- CRDF 13.03
- XGN 31.85
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.